Terms: = Prostate cancer AND BUB1B, BUBR1, 701, ENSG00000156970, SSK1, BUB1beta, MAD3L, hBUBR1, Bub1A, O60566 AND Diagnosis
27 results:
1. Identification of the Key Genes Involved in the Tumorigenesis and Prognosis of prostate cancer.
Wang W; Wu Q; Mohyeddin A; Liu Y; Liu Z; Ge J; Zhang B; Shi G; Wang W; Wu D; Wang F
Comput Math Methods Med; 2022; 2022():5500416. PubMed ID: 36245843
[TBL] [Abstract] [Full Text] [Related]
2. Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer.
Hakozaki Y; Yamada Y; Kawai T; Nakamura M; Takeshima Y; Iwaki T; Teshima T; Kinoshita Y; Fujii Y; Akiyama Y; Sato Y; Yamada D; Suzuki M; Kashiwagi-Hakozaki M; Ushiku T; Kume H
Sci Rep; 2022 Sep; 12(1):16202. PubMed ID: 36171391
[TBL] [Abstract] [Full Text] [Related]
3. Environmental Phenol and Paraben Exposure Risks and Their Potential Influence on the Gene Expression Involved in the Prognosis of prostate cancer.
Alwadi D; Felty Q; Roy D; Yoo C; Deoraj A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409038
[TBL] [Abstract] [Full Text] [Related]
4. Associations between comorbidities and advanced stage diagnosis of lung, breast, colorectal, and prostate cancer: A systematic review and meta-analysis.
Boakye D; Günther K; Niedermaier T; Haug U; Ahrens W; Nagrani R
Cancer Epidemiol; 2021 Dec; 75():102054. PubMed ID: 34773768
[TBL] [Abstract] [Full Text] [Related]
5. Construction of Potential Gene Expression and Regulation Networks in prostate cancer Using Bioinformatics Tools.
Liu H; Li L; Fan Y; Lu Y; Zhu C; Xia W
Oxid Med Cell Longev; 2021; 2021():8846951. PubMed ID: 34512870
[TBL] [Abstract] [Full Text] [Related]
6. Influence of sociodemographic factors on treatment's choice for localized prostate cancer in Portugal.
Pereira-Lourenço M; Vieira E Brito D; Peralta JP; Godinho R; Conceiçao P; Reis M; Rabaça C; Sismeiro A
Arch Ital Urol Androl; 2020 Apr; 92(1):45-49. PubMed ID: 32255317
[TBL] [Abstract] [Full Text] [Related]
7. Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical prostatectomy.
Martini A; Marqueen KE; Falagario UG; Waingankar N; Wajswol E; Khan F; Fossati N; Briganti A; Montorsi F; Tewari AK; Stock R; Rastinehad AR
JAMA Netw Open; 2020 Mar; 3(3):e201913. PubMed ID: 32232450
[TBL] [Abstract] [Full Text] [Related]
8. Extent of Food Processing and Risk of prostate cancer: The PROtEuS Study in Montreal, Canada.
Trudeau K; Rousseau MC; Parent MÉ
Nutrients; 2020 Feb; 12(3):. PubMed ID: 32121075
[TBL] [Abstract] [Full Text] [Related]
9. Factors Associated With Lymphedema in Women With Node-Positive Breast cancer Treated With Neoadjuvant Chemotherapy and Axillary Dissection.
Armer JM; Ballman KV; McCall L; Ostby PL; Zagar E; Kuerer HM; Hunt KK; Boughey JC
JAMA Surg; 2019 Sep; 154(9):800-809. PubMed ID: 31314062
[TBL] [Abstract] [Full Text] [Related]
10. Insurance status as a modifier of the association between race and stage of prostate cancer diagnosis in Florida during 1995 and 2013.
Ramirez E; Morano J; Beguiristain T; Castro G; de la Vega PR; Nieder AM; Barengo NC
Cancer Epidemiol; 2019 Apr; 59():104-108. PubMed ID: 30731402
[TBL] [Abstract] [Full Text] [Related]
11. Comparison of prostate Biopsy with or without Prebiopsy Multiparametric Magnetic Resonance Imaging for prostate cancer Detection: An Observational Cohort Study.
Bryant RJ; Hobbs CP; Eyre KS; Davies LC; Sullivan ME; Shields W; Sooriakumaran P; Verrill CL; Gleeson FV; MacPherson RE; Hamdy FC; Brewster SF
J Urol; 2019 Mar; 201(3):510-519. PubMed ID: 30266332
[TBL] [Abstract] [Full Text] [Related]
12. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the prostate in Patients with Primary Bone Metastatic prostate cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS; Hulshof MCCM; Vis AN; Zwinderman AH; Twisk JWR; Witjes WPJ; Delaere KPJ; Moorselaar RJAV; Verhagen PCMS; van Andel G
Eur Urol; 2019 Mar; 75(3):410-418. PubMed ID: 30266309
[TBL] [Abstract] [Full Text] [Related]
13. Differences in cancer survival between immigrants in Norway and the host population.
Thøgersen H; Møller B; Robsahm TE; Babigumira R; Aaserud S; Larsen IK
Int J Cancer; 2018 Dec; 143(12):3097-3105. PubMed ID: 29987865
[TBL] [Abstract] [Full Text] [Related]
14. Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL; Johansson PA; Nathan V; Howlie M; Symmons J; Palmer JM; Hayward NK
PLoS One; 2018; 13(4):e0194098. PubMed ID: 29641532
[TBL] [Abstract] [Full Text] [Related]
15. Disparities in hospitalization outcomes among African-American and White prostate cancer patients.
Naik G; Akinyemiju T
Cancer Epidemiol; 2017 Feb; 46():73-79. PubMed ID: 28056390
[TBL] [Abstract] [Full Text] [Related]
16. Digoxin use after diagnosis of prostate cancer and survival: a population-based cohort study.
Karasneh RA; Murray LJ; Hughes CM; Cardwell CR
Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1099-103. PubMed ID: 27146482
[TBL] [Abstract] [Full Text] [Related]
17. PCA3-based nomogram for predicting prostate cancer and high grade cancer on initial transrectal guided biopsy.
Elshafei A; Chevli KK; Moussa AS; Kara O; Chueh SC; Walter P; Hatem A; Gao T; Jones JS; Duff M
Prostate; 2015 Dec; 75(16):1951-7. PubMed ID: 26384170
[TBL] [Abstract] [Full Text] [Related]
18. Metformin use and prostate cancer risk.
Preston MA; Riis AH; Ehrenstein V; Breau RH; Batista JL; Olumi AF; Mucci LA; Adami HO; Sørensen HT
Eur Urol; 2014 Dec; 66(6):1012-20. PubMed ID: 24857538
[TBL] [Abstract] [Full Text] [Related]
19. Comparative effectiveness of aggressive versus nonaggressive treatment among men with early-stage prostate cancer and differing comorbid disease burdens at diagnosis.
Daskivich TJ; Lai J; Dick AW; Setodji CM; Hanley JM; Litwin MS; Saigal C;
Cancer; 2014 Aug; 120(16):2432-9. PubMed ID: 24824511
[TBL] [Abstract] [Full Text] [Related]
20. Commentary on "secondary cancers after intensity-modulated radiotherapy, brachytherapy, and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention." Zelefsky MJ, Pei X, Teslova T, Kuk D, Magsanoc JM, Kollmeier M, Cox B, Zhang Z. Department of Radiation Oncology, Memorial Sloan-Kettering cancer Center, New York, NY.: BJU Int 2012;110:1696-701. doi: 10.1111/j.1464-410X.2012.11385.x. [Epub 2012 Aug 13].
Gottschalk A
Urol Oncol; 2014 Feb; 32(2):209. PubMed ID: 24445290
[TBL] [Abstract] [Full Text] [Related]
[Next]
